Indeed, the mechanisms underlying ERα downregulation in non-luminal breast cancer cells have already been scrutinized and several promising strategies to restore ERα expression are currently under evaluation (reviewed in [36,37]). This evidence concerns the gene ESR1 and breast carcinoma.